Bleomycin Sulfate is a chemotherapeutic agent commonly used for Hodgkin’s lymphoma. Bleomycin is a mixture of Bleomycin A2 and Bleomycin B2. The approximate composition of A2:B2 is 2:1. The compound is water soluble.
We also offer:
- Bleomycin (B053)
- Bleomycin A2 Sulfate (B019)
- Bleomycin A5 Hydrochloride (B004)
- Demethylbleomycin A2 Sulfate, EvoPure® (D023)
|Mechanism of Action||The mechanism of action Bleomycin Sulfate is not well defined; however, it is thought to chelate metallic ions which decreases enzyme activity and stability. This effect is believed to cause the enzymes to react with oxygen, producing free radicals which create single stranded breaks in deoxyribose sugar. |
Bleomycin's anticancer activities include the increase of caspase-3 and p53, and the inhibition of telomerase activity leading to apoptosis. The anti-cancer properties derives from its ability to affect DNA cleavage in cancer cells.
|Cancer Applications||Bleomycin contains a disaccharide moiety composed of 2 unusual sugars, L-gulose and 3-O-carbamoyl-D-mannose. Bleomycin could be regarded as a modular system composed of a tumor-targeting agent (the dissacharide moiety) and a tumoricidal agent (deglycobleomycin). The disaccharide moiety is responsible for the tumor cell targeting properties of Bleomycin. Bleomycin analogs were prepared, the glycosylated analogs were more cytotoxic to cultured DU145 prostate cancer cells. These findings establish a role for the Bleomycin disaccharide in tumor targeting/uptake and suggest that the disaccharide moiety may be capable of delivering other cytotoxins to cancer cells. Cytotoxicity testing with DU145 human prostate cancer cells in vitro (Schroeder et al, 2014). |
Bleomycin is used in combination with other antineoplastic agents in studying lymphomas, testicular carcinomas, and squamous cell carcinomas. In this report, we found that the human L-carnitine transporter (hCT2) is involved in Bleomycin-A5 uptake. NT2/D1 human testicular cancer cells which highly express hCT2 are very sensitive to Bleomycin-A5. Data suggest that hCT2 can mediate the uptake of Bleomycin A5 (Aouida M et al, 2010).
Aouida M, Poulin P and Ramotar (2010) The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue Bleomycin-A5. J. Biol. Chem. 285:6275-6284
Aszalos A, Crawford J, Vollmer P, Kantor N and Alexander T (1981) High-performance liquid chromatographic determination of components of Bleomycin preparations. J. Pharm. Sci 70(8):878-880 PMID 6171636
Dorr, RT (1991) Bleomycin Pharmacology: Mechanism of action and resistance, and clinical pharmacokinetics. Semin. Oncol. 19(2): 3-8 PMID 1384141
Schroeder BR et al (2014) The disaccharide moiety of bleomycin facilitates uptake by cancer cells. J. Am. Chem Soc. 136(39):13641-13656
Takita T et al (1972) Chemistry of bleomycin. IX. The structures of Bleomycin and phleomycin. J. Antibiot. (Tokyo) 25:755-757 PMID 4119701